DEDIFFERENTIATED CHONDROSARCOMA
Clinical trials for DEDIFFERENTIATED CHONDROSARCOMA explained in plain language.
Never miss a new study
Get alerted when new DEDIFFERENTIATED CHONDROSARCOMA trials appear
Sign up with your email to follow new studies for DEDIFFERENTIATED CHONDROSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy drug shows promise for rare sarcomas in early trial
Disease control OngoingThis study tested the drug atezolizumab in 27 people with rare cancers called chondrosarcoma and clear cell sarcoma that could not be removed by surgery or had spread. The drug helps the body's immune system attack cancer cells. The main goal was to see if tumors shrank or stoppe…
Matched conditions: DEDIFFERENTIATED CHONDROSARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 07:07 UTC
-
Personalized cell therapy takes on resistant cancers
Disease control OngoingThis study tests a treatment made from a patient's own immune cells (called LN-145) for cancers like ovarian, triple-negative breast, anaplastic thyroid, and bone sarcomas that have not responded to standard therapy or have returned. The cells are taken from the tumor, grown in a…
Matched conditions: DEDIFFERENTIATED CHONDROSARCOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 07:05 UTC
-
Could a targeted drug halt rare bone cancer?
Disease control OngoingThis study tested a drug called vismodegib in 45 people with advanced chondrosarcoma, a rare bone cancer that has spread and is hard to treat. The goal was to see if the drug could shrink tumors or stop them from growing for at least 6 months. While not a cure, the approach aims …
Matched conditions: DEDIFFERENTIATED CHONDROSARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:47 UTC